Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: The Dodgy Ticker who wrote (3057)	5/4/1999 9:58:00 AM
From: Silver Knife	Respond to of 3702

Techniclone Treats First Newly Diagnosed Glioblastoma -Brain Cancer- Patient in Its Cotara Phase II Clinical Trial Tuesday May 4, 7:31 am Eastern Time TUSTIN, Calif.--(BUSINESS WIRE)--May 4, 1999--Techniclone Corporation (NASDAQ:TCLN - news) a developer of leading-edge unique therapeutics for the advanced treatment of cancer, today announced that the Company has enrolled and is treating its first patient with newly diagnosed glioblastoma multiforme (brain cancer) in its Phase II clinical trial utilizing Cotara(TM), the trademarked name for Techniclone's Tumor Necrosis Therapy (TNT), a chimeric monoclonal antibody labeled with an Iodine-131 radioisotope. The patient is being treated at the Medical University of South Carolina (MUSC) under the direction of Dr. Sunil Patel (Principal Investigator). Dr. John Bonfiglio, Vice President of Technology and Business Development at Techniclone, stated, ''This Cotara(TM) treatment of our first patient with newly diagnosed glioblastoma, under the ongoing Phase II protocol, represents another milestone in the Company's clinical trial process. Glioblastoma is a deadly form of brain cancer with no satisfactory treatment options. The data generated from this study will assist us in understanding how to best utilize this exciting therapy against this terrible form of cancer.'' Cotara(TM) binds to dead/decaying cells found in the core of solid tumors. In addition to the Phase II clinical trials in the U.S. for malignant glioma, a Phase I/II clinical trial will commence soon in Mexico City for the treatment of solid tumors (pancreatic, prostate and liver cancer). Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercializing and licensing of unique technologies for the treatment of cancer, primarily based on its ''collateral targeting technologies.'' These technologies therapeutically target cell structure and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. In addition to Cotara(TM), the Company has a direct tumor targeting agent called Oncolym(TM) for the treatment of advanced non-Hodgkin's B-cell Lymphoma, that is currently undergoing Phase II/III human testing. Techniclone recently entered into a worldwide Licensing Agreement for Oncolym with Schering AG, Germany. Two other collateral targeting agents, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA) are in pre-clinical stages of development. VEAs are monoclonal antibodies that increase tumor blood vessel permeation for enhanced uptake of chemotherapeutic agents versus normal tissues, while VTAs are agents that block the flow of oxygen/nutrients to a solid tumor's vascular network, causing clotting and necrosis. VTAs also can deliver a wide variety of therapeutic agents to a solid tumor, including therapeutic agents, biologic agents, toxins and radioisotopes. Additional information on the Company and its products can be found at www.techniclone.com. Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10Q for the quarter ended January 31, 1999 and Form 10K for the year ended April 30, 1998. Contact: Investor Relations: Cynthia DeMonte, 212-420-0088 or Media Relations: Clint Cantwell/Rubenstein PR, 212-843-8051